Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Importance The humanized monoclonal antibody atezolizumab targets programmed death-
ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple …

Background Guidelines recommend atezolizumab plus nab-paclitaxel (A+ nP) for first-line
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …

Background Immunotherapy in combination with chemotherapy has shown promising
efficacy across many different tumour types. We report the prespecified second interim …

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast
cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled …

Atezolizumab (Tecentriq®), an immune checkpoint inhibitor against programmed death
ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination …

Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …

Background Understanding the impact of the tumor immune microenvironment and
BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint …

1009 Background: Atezolizumab (atezo; MPDL3280A) is a humanized MAb that inhibits
binding of PD-L1 to PD-1 and B7. 1, thus restoring tumor-specific T-cell immunity. Atezo has …

Background Metastatic triple-negative breast cancer (mTNBC) is incurable. A key treatment
goal is providing palliation while maintaining patients' health-related quality of life (HRQoL) …